Anti-CD38 and Anti-CD47 Interference in the Blood Bank and Ways to Resolve Them

 

Biological therapies can be highly effective in treating malignancies but can cause interference with blood bank testing. Two monoclonal therapies directed at cluster designation antigens that cause red blood cell agglutination are highlighted: CD38 and CD47. This lecture will review the serologic reactivity and methods to abrogate blood bank interference.

Originally published on June 5, 2023

Lecture Presenter

Waseem Anani, MD

Waseem Anani, MD

Associate Professor (Clinical)
University of Utah School of Medicine
Medical Director, Immunohematology Reference Laboratory and Blood Services
ARUP Laboratories

Dr. Waseem Anani is the medical director of the ImmunohematologY Reference Laboratory and Blood Services at ARUP Laboratories, and an associate professor (clinical) for the University of Utah School of Medicine. He received his medical degree from Penn State College of Medicine. He then completed his residency in clinical pathology at the University of Pittsburgh and a fellowship in transfusion medicine from the Medical College of Wisconsin. Dr. Anani is board certified by the American Board of Pathology in clinical pathology and transfusion medicine. His research interests include glycomics and immunohematology.

Objectives

After this presentation, participants will be able to:

  • Describe the serologic findings from anti-CD38 and anti-CD47
  • List the methods to overcome interference
  • Explain the benefits and drawbacks of each method describe

Sponsored by:

University of Utah School of Medicine, Department of Pathology, and ARUP Laboratories